FIELD: chemistry; pharmaceutics.
SUBSTANCE: invention relates to a method of inhibiting a viral infection in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of compound 1 or a pharmaceutically acceptable salt thereof, wherein the viral infection is a coronavirus infection caused by SARS-CoV-2. Invention also relates to use of a pharmaceutical composition for inhibiting coronavirus infection in a person in need thereof, to the use of compound 1 in inhibiting infection caused by SARS-CoV-2in humans, to the use of compound 1 in the manufacture of a medicinal product for inhibiting coronavirus infection.
EFFECT: inhibition of viral infection caused by SARS-CoV-2.
15 cl, 10 dwg, 4 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC AGENT AGAINST CORONAVIRUS INCLUDING AN ELAEOCARPUS SYLVESTRIS EXTRACT | 2021 |
|
RU2780346C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING POLYNUCLEOTIDES, AND USE THEREOF FOR PREVENTING OR TREATING COVID-19 | 2021 |
|
RU2824489C1 |
| METHODS FOR TREATING INFECTIOUS DISEASES CAUSED BY CORONAVIRUS | 2021 |
|
RU2772701C1 |
| METHOD FOR THE TREATMENT OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2021 |
|
RU2775966C1 |
| TRIAZINE DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST VIRUS REPLICATION, AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | 2022 |
|
RU2806042C1 |
| PHILLYRIN AND ITS DERIVATIVES FOR SUPPRESSION OF THE 3CLPRO PROTEIN AND FIGHTING THE COVID-19 VIRUS | 2021 |
|
RU2804307C1 |
| NEW APPLICATION OF NATURAL DOUBLE-STRANDED RNAS FOR THE TREATMENT AND/OR PREVENTION OF VIRAL INFECTIONS | 2022 |
|
RU2781903C1 |
| USING DALARGIN FOR PRODUCING AGENTS FOR TREATING COVID-19 CORONAVIRUS INFECTION | 2020 |
|
RU2728939C1 |
| COMBINED DRUG WITH ANTIVIRAL EFFECT AGAINST NEW SARS-COV-2 CORONAVIRUS | 2021 |
|
RU2746362C1 |
| WHOLE VIRION INACTIVATED VACCINE AGAINST SARS-Cov-2 INFECTION AND ITS USE | 2023 |
|
RU2809375C1 |
